Exchange Traded Concepts LLC Buys 1,075 Shares of Insulet Corporation (NASDAQ:PODD)

Exchange Traded Concepts LLC lifted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 225.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,552 shares of the medical instruments supplier's stock after buying an additional 1,075 shares during the quarter. Exchange Traded Concepts LLC's holdings in Insulet were worth $408,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new position in shares of Insulet in the fourth quarter worth about $36,000. Itau Unibanco Holding S.A. bought a new position in shares of Insulet in the fourth quarter worth about $42,000. SRS Capital Advisors Inc. raised its stake in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after buying an additional 56 shares during the period. Assetmark Inc. raised its stake in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after buying an additional 246 shares during the period. Finally, Coppell Advisory Solutions LLC raised its stake in shares of Insulet by 135.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock worth $74,000 after buying an additional 162 shares during the period.

Analyst Upgrades and Downgrades

PODD has been the topic of several recent research reports. Citigroup reaffirmed a "buy" rating and issued a $380.00 price objective (up previously from $320.00) on shares of Insulet in a research note on Thursday, May 22nd. Oppenheimer lifted their target price on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Wells Fargo & Company set a $322.00 target price on Insulet in a research note on Monday, April 28th. The Goldman Sachs Group assumed coverage on Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 target price on the stock. Finally, Raymond James Financial reissued an "outperform" rating and set a $360.00 target price (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $321.00.

Insiders Place Their Bets

In other news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president now owns 23,180 shares in the company, valued at $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares in the company, valued at approximately $888,525. This trade represents a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by company insiders.

Insulet Stock Up 0.5%

Shares of PODD opened at $303.15 on Friday. Insulet Corporation has a 52 week low of $173.00 and a 52 week high of $329.33. The company has a quick ratio of 3.63, a current ratio of 4.47 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $21.34 billion, a price-to-earnings ratio of 54.52, a PEG ratio of 2.71 and a beta of 1.37. The stock's 50-day moving average price is $291.86 and its 200-day moving average price is $276.25.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. Insulet's revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.73 earnings per share. On average, sell-side analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.